ISB 1442

ISB 1442 is a fully human, first-in-class biparatopic bispecific antibody designed to target both CD38 and CD47 cell surface glycoproteins. Developed using the BEAT (Bispecific Engagement by Antibodies based on the TCR) platform, it features two anti-CD38 arms that bind distinct epitopes on tumor cells, enabling avidity-induced blocking of adjacent CD47 receptors. The anti-CD47 arm blocks the interaction between CD47 and signal-regulatory protein alpha (SIRPα), disrupting a key "don't eat me" signal used by cancer cells to evade immune clearance. The Fc region of ISB 1442 is engineered to enhance effector functions including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Preclinical studies have shown that ISB 1442 has superior tumor cell killing compared to daratumumab or combinations of daratumumab with an anti-CD47 monoclonal antibody, with minimal off-tumor effects such as red blood cell depletion. It is being developed primarily for relapsed/refractory multiple myeloma but may have potential in other hematological malignancies[3][4][5][6].

Other names

anti-CD38/anti-CD47 bispecific antibody ISB 1442biparatopic bispecific antibody targeting CD38 and CD47